2,017 followers
10. We also discussed the role of dose-reduced #HMA therapy (azacitidine or decitabine) for lower-risk MDS refractory to first-line therapies! (11/12) https://t.co/qg6BUpg4qx https://t.co/z9E1E6TNy5
41,275 followers
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS | NEJM Evidence https://t.co/cq4OmPN7HO
3,222 followers
RT @NEJMEvidence: In this editorial, Rafael Bejar, MD, PhD, from @UCSDCancer reviews the trial by Sasaki et al. on the long-term efficacy o…
1,476 followers
RT @NEJMEvidence: In this editorial, Rafael Bejar, MD, PhD, from @UCSDCancer reviews the trial by Sasaki et al. on the long-term efficacy o…